Quantiferon®-TB gold in the identifi cation of latent tuberculosis infection in rheumatoid arthritis: A pilot study

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 11, 2009, Pages 1427-1432

  Shovman, O ^a   Anouk, M ^a   Vinnitsky, N ^a   Arad, U ^a   Paran, D ^a   Litinsky, I ^a   Caspi, D ^a   Elkayam, O ^a,b,c  

^a Departments of Rheumatology   (China)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INFECTION RISK; INTERMETHOD COMPARISON; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; ANALYTICAL EQUIPMENT; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; IMMUNOLOGY; LATENT TUBERCULOSIS; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM; PREDICTION AND FORECASTING; RADIOGRAPHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; METHOTREXATE; MIDDLE AGED; MYCOBACTERIUM; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PREDNISONE; QUESTIONNAIRES; REAGENT KITS, DIAGNOSTIC; TUBERCULIN TEST;

EID: 73949117825     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 714-720.
2. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Myco-bacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-805.
3. Provenzano G, Ferrante M C, Simon G. TB screening and anti-TNF alpha treatment. Thorax 2005; 60: 613.
4. Wang L, Turner M O, Elwood R K, Schulzer M, FitzGerald J M. A meta-analysis of the effect of bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804-809.
5. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, et al. Attenuated response to purif ed protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361.
6. Helliwell M G, Panayi G S, Unger A. Delayed cutaneous hyper-sensitivity in rheumatoid arthritis: the inf uence of nutrition and drug therapy. Clin Rheumatol 1984; 3: 39-45.
7. Paimela L, Johansson-Stephansson E A, Koskimies S, Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 1990; 8: 433-437.
8. Smith M D, Smith A, O'Donnell J, Ahern M J, Roberts-Thomson P J. Impaired delayed-type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy. Ann Rheum Dis 1989; 48: 108-113.
9. Mori T, Sakatani M, Yamagishi F, et al. Specif c detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64.
10. Lalvani A, Pathan A A, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specif c T cells. Am J Respir Crit Care Med 2001; 163: 824-828.
11. Mazurek G H, Villarino M E; Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR 2003; 52: 15-18.
12. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON-TB Gold test as part of a screening programme in patients with rheumatoid arthritis under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007; 46: 1035-1036. (Pubitemid 47062518)
13. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during inf iximab administration. Rheumatol Int 2007; 27: 1143-1148.
14. Kaushik V V, Ambalavanan S, Binymin K. Comment on: use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007; 46: 1863-1864; author reply 1864-1865.
15. Efthimiou P, Sood S. QuantiFERON-TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007; 66: 276.
16. Greenberg J D, Reddy S M, Schloss S G, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobac-terium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008; 35: 770-775. Erratum in: J Rheumatol 2008; 35: 943.
17. Ponce de Leon D, Acevedo-Vásquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-781.
18. Bocchino M, Matarese A, Bellof ore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-913.
19. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro-s pecif c blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-1615.
20. Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classif-cation of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
21. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR 2000; 49: 1-51.
22. Keane J, Bresnihan B. Tuberculosis reactivation during immuno-suppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20: 443-449.
23. EuroTB: surveillance of TB in Europe. Saint Maurice, France: EuroTB. http://www.eurotb.org/Accessed September 2008.
24. Mazurek G H, LoBue P A, Daley C L, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
25. Yates A B, Deshazo R D. Delayed hypersensitivity skin testing. Immun Allergy Clinics North America 2001; 21: 383-397.
26. Pope R M, Kniker W T, Talal N, Dauphinee M. Delayed-type hypersensitivity in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 17-20.
27. van Roon J A, Verhoef C M, van Roy J L, et al. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 1997; 56: 656-660.
28. Klimiuk P A, Sierakowski S, Latosiewicz R, Cylwik B, Skow-ronski J, Chwiecko J. Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol 2001; 28: 1211-1217.
29. Austrup F, Vestweber D, Borges E, et al. P-and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inf ammed tissues. Nature 1997; 385: 81-83.
30. Matulis G, Jüni P, Villiger P M, Gadola S D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specif c interferon gamma assay. Ann Rheum Dis 2008; 67: 84-90.